A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19)
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) as a life-threatening disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is accounted as global public health concern. Treatment of COVID-19 is primarily supportive and the role of antiviral agents is yet to be established. However, there are no specific anti-COVID-19 drugs and vaccine until now. This review focuses on traditional medicine such as medicinal plant extracts as promising approaches against COVID-19. Chinese, Indian and Iranian traditional medicine, suggests some herbs for prevention, treatment and rehabilitation of the diseases including COVID-19. Although, inhibition of viral replication is considered as general mechanism of herbal extracts, however some studies demonstrated that traditional herbal extracts can interact with key viral proteins which are associated with virus virulence. Chinese, Indian and Iranian traditional medicine, suggests some herbs for prevention, treatment and rehabilitation of the diseases including COVID-19. However the beneficial effects of these traditional medicines and their clinical trials remained to be known. Herein, we reviewed the latest updates on traditional medicines proposed for treatment of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · cited 1×
“So, IFNα can be considered as a drug candidate for COVID-19 therapy [29].”
BackgroundGuo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
Wu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30360-3 · Cited by 3,919 · cited 1×
“However, randomized double-blinded clinical trials with large sample sizes should be used as the standard to determine whether antiviral drugs could be used in clinical practice [46,47].”
BackgroundA Review of Coronavirus Disease-2019 (COVID-19)
Singhal, T. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03263-6 · Cited by 3,537 · cited 3×
“The common principles are maintaining hydration, nutrition condition and controlling the fever [4].”
BackgroundInfluentialCOVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662 · cited 1×
“The anti-viral and anti-inflammatory activities of chloroquine are practical choice in preventing COVID-19-related pneumonia [36].”
BackgroundLiu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707 · cited 1×
“CTM could be an alternative strategy for the prevention of COVID-19 in high-risk populations [12].”
MethodPubChem: a public information system for analyzing bioactivities of small molecules
Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., & Bryant, S. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp456 · Cited by 1,467
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416 · cited 1×
“Remdesivir (GS-5734) as a nucleoside analogue was shown to inhibit SARS-CoV and MERS-CoV in in-vitro [32].”
BackgroundReview of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)
Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., & Xia, Z. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05762-w · Cited by 1,410 · cited 1×
“The SARS-CoV-2 can enter to respiratory cells via the angiotensin-converting enzyme 2 (ACE-2) receptor [18].”
BackgroundReal-time RT-PCR in COVID-19 detection: issues affecting the results
Tahamtan, A., & Ardebili, A. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1757437 · Cited by 1,217 · cited 1×
“In patients with severe disease, bilateral pulmonary parenchymal grounded-glass shadow and nodules is observed [26].”
BackgroundReview of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
Wang, L., Wang, Y., Ye, D., & Liu, Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105948 · Cited by 1,193
Coronavirus disease 2019 (COVID-19): current status and future perspectives
Li, H., Liu, S.-M., Yu, X.-H., Tang, S.-L., & Tang, C.-K. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105951 · Cited by 1,156
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038 · cited 2×
“The results showed that this regimen prescription could resolve the symptoms and improvement without side effects [47].”
BackgroundYang, Y., Islam, M. S., Wang, J., Li, Y., & Chen, X. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45538 · Cited by 960 · cited 2×
“Consequently, CTM may be effective in the treatment of severe patients with the ability to prevent cytokine storm and its disturbing consequences [67].”
BackgroundDeployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 765 · cited 1×
“However, the clinical tests have begun since March 5, 2020 and after success in the clinical tests, the products should be confirmed by the food and drug organization [14,83,84].”
BackgroundSARS-CoV-2 and COVID-19: The most important research questions
Yuen, K.-S., Ye, Z. W., Fung, S.-Y., Chan, C.-P., & Jin, D.-Y. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00404-4 · Cited by 707 · cited 1×
“Study of a large number infected patients found out that the main transmission route of SARS-CoV-2 is person-person contact [24].”
BackgroundTraditional Chinese medicine for COVID-19 treatment
Ren, J.-L., Zhang, A.-H., & Wang, X.-J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104743 · Cited by 693 · cited 1×
“macrocephala, and Saposhnikoviae Radix [102] A.”
A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Tu, Y.-F., Chien, C.-S., Yarmishyn, A. A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., Lai, W.-Y., Yang, D.-M., Chou, S.-J., Yang, Y.-P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072657 · Cited by 686
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649 · cited 1×
“Some studies have shown that the Glycyrrhiza glabra and Allium sativum have inhibitory effect on SARS-CoV replication and then they can be considered as a promising drug candidate for COVID-19 [75].”
BackgroundCOVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636 · cited 2×
“Kaletra was used as a protease inhibitor for human immunodeficiency virus [16] which interferes with viral replication.”
BackgroundMethodIdentification of natural compounds with antiviral activities against SARS-associated coronavirus
LI, S., CHEN, C., ZHANG, H., GUO, H., WANG, H., WANG, L., ZHANG, X., HUA, S., YU, J., & XIAO, P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.02.007 · Cited by 602
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
HO, T., WU, S., CHEN, J., LI, C., & HSIANG, C. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.014 · Cited by 516 · cited 1×
“Similarly, some medicinal plant extracts including Rheum officinale, Polygonum multiflorum, emodin and some other active components of these herbs were found to inhibit the bindings of SARS-CoV (S) spike protein to ACE2 with IC50 values between 1 and 10 μg/mL, and 200 μM for emodin [55].”
BackgroundDrug targets for corona virus: A systematic review
Medhi, B., Prajapat#, M., Sarma#, P., Shekhar#, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., et al. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_115_20 · Cited by 496 · cited 1×
“The WHO, European Medicines Agency [7], US Food and Drug Administration (FDA) and the Chinese government and drug manufacturers are coordinating with researchers and industrials to accelerate the development of new drugs for COVID-19 [8].”
Background(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0773 · Cited by 486 · cited 1×
“One of the promising monoclonal antibodies can be CR3022 due to its binding affinity to virus for the treatment of COVID-19 [40].”
BackgroundBiological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Clinical trials on drug repositioning for COVID-19 treatment
Rosa, S. G. V., & Santos, W. C. (2020) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2020.40 · Cited by 420
Coronavirus Disease 2019 (COVID‐19)
(2020) · Journal of Midwifery & Women's Health · doi:10.1111/jmwh.13196 · Cited by 391
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Lythgoe, M. P., & Middleton, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 380 · cited 8×
“In addition, many randomized clinical trials are being performed about Arbidol efficiency on COVID-19 infection in China [19].”
BackgroundInfluentialBi-directional differentiation of single bronchioalveolar stem cells during lung repair
Liu, K., Tang, M., Liu, Q., Han, X., Jin, H., Zhu, H., Li, Y., He, L., Ji, H., & Zhou, B. (2020) · Cell Discovery · doi:10.1038/s41421-019-0132-8 · Cited by 360
COVID-19: faecal–oral transmission?
Hindson, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0295-7 · Cited by 332
Cao, Y.-C., Deng, Q.-X., & Dai, S.-X. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101647 · Cited by 320
Croup Is Associated with the Novel Coronavirus NL63
van der Hoek, L., Sure, K., Ihorst, G., Stang, A., Pyrc, K., Jebbink, M. F., Petersen, G., Forster, J., Berkhout, B., & Überla, K. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020240 · Cited by 308
Chiow, K. H., Phoon, M. C., Putti, T., Tan, B. K. H., & Chow, V. T. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2015.12.002 · Cited by 272
Liu, Y., Zhang, C., Huang, F., Yang, Y., Wang, F., Yuan, J., Zhang, Z., Qin, Y., Li, X., Zhao, D., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa037 · Cited by 269
Korytkowski, M., Bell, D., Jacobsen, C., Suwannasari, R., & FlexPen® Study Team (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80337-5 · Cited by 267
Herbal plants and plant preparations as remedial approach for viral diseases
Ganjhu, R. K., Mudgal, P. P., Maity, H., Dowarha, D., Devadiga, S., Nag, S., & Arunkumar, G. (2015) · VirusDisease · doi:10.1007/s13337-015-0276-6 · Cited by 219 · cited 3×
“In conclusion, more studies are needed to perform for Indian medicinal plants in order to the design and development of drug specific to COVID-19 [79].”
BackgroundYang, R., Liu, H., Bai, C., Wang, Y., Zhang, X., Guo, R., Wu, S., Wang, J., Leung, E., Chang, H., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104820 · Cited by 217 · cited 3×
“The Ma Xin Gan Shi and Da Yun Yin decoction were evaluated for the treatment of SARS-CoV [61].”
BackgroundMethodInfluentialAntiviral activity of plants and their isolated bioactive compounds: An update
Denaro, M., Smeriglio, A., Barreca, D., De Francesco, C., Occhiuto, C., Milano, G., & Trombetta, D. (2020) · Phytotherapy Research · doi:10.1002/ptr.6575 · Cited by 186 · cited 1×
“Natural products and their derivatives have potential activities in the treatment of viral infections [9,10].”
BackgroundThe Emerging Role of Vitamin C as a Treatment for Sepsis
Kashiouris, M. G., L’Heureux, M., Cable, C. A., Fisher, B. J., Leichtle, S. W., & Fowler, A. A. (2020) · Nutrients · doi:10.3390/nu12020292 · Cited by 177
Ulasli, M., Gurses, S. A., Bayraktar, R., Yumrutas, O., Oztuzcu, S., Igci, M., Igci, Y. Z., Cakmak, E. A., & Arslan, A. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3019-7 · Cited by 162
Wen, C.-C., Shyur, L.-F., Jan, J.-T., Liang, P.-H., Kuo, C.-J., Arulselvan, P., Wu, J.-B., Kuo, S.-C., & Yang, N.-S. (2011) · Journal of Traditional and Complementary Medicine · doi:10.1016/s2225-4110(16)30055-4 · Cited by 161
Li, Y., Liu, X., Guo, L., Li, J., Zhong, D., Zhang, Y., Clarke, M. J., & Jin, R. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01343-4 · Cited by 159 · cited 1×
“The first case of COVID -19 cured and discharged from hospital by prescription of CTM was reported on 24 January 2020 in Beijing [64].”
BackgroundTherapeutic strategies for critically ill patients with COVID-19
Li, L., Li, R., Wu, Z., Yang, X., Zhao, M., Liu, J., & Chen, D. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00661-z · Cited by 147 · cited 1×
“So, the administration of Ta1 can be used as drug candidate for COVID-19 treatment [37,38].”
MethodTraditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP)
Du, H., Hou, X., Yu-Huan, M. I. A. O., et al. (2020) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(20)30022-4 · Cited by 145
Screening of Indonesian plant extracts for anti‐human immunodeficiency virus—type 1 (HIV‐1) activity
Otake, T., Mori, H., Morimoto, M., Noboru, U. E. B. A., Sutardjo, S., Kusumoto, I. T., Hattori, M., & Namba, T. (1995) · Phytotherapy Research · doi:10.1002/ptr.2650090103 · Cited by 141 · cited 1×
“Some medicinal plants such as Acacia nilotica, Eugenia jambolana and Euphorbia granulate have also shown inhibitory effect on HIV protease and these plants can be considered as drug candidate for COVID-19 [77].”
BackgroundKim, H., Shin, H., Park, H., Kim, Y., Yun, Y. G., Park, S., Shin, H., & Kim, K. H. (2007) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.10.011 · Cited by 129
Application of Chinese Medicine in Acute and Critical Medical Conditions
Luo, Y., Wang, C., Hesse-Fong, J., Lin, J., & Yuan, C. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500629 · Cited by 128 · cited 1×
“demonstrated that the aqueous extract of Houttuynia cordata can inhibit two efficient protein namely chymotrypsin-like protease (3CLpro) and RdRp in SARS-CoV [53].”
BackgroundStatistical evidence for the usefulness of Chinese medicine in the treatment of SARS
Chen, Z., & Nakamura, T. (2004) · Phytotherapy Research · doi:10.1002/ptr.1485 · Cited by 124 · cited 2×
“These herbal ingredients has therapeutic benefits for respiratory tract infections especially COVID-19 [62,63].”
BackgroundYang, C., Lee, Y., Kang, I., Barnard, D. L., Jan, J., Lin, D., Huang, C.-W., Yeh, T., Chao, Y., & Lee, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.08.009 · Cited by 106
Hussain, F., Jahan, N., Rahman, K.-U., Sultana, B., & Jamil, S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4643736 · Cited by 93
Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence
Zhang, M., Liu, X.-M., & He, L. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i23.3500 · Cited by 85 · cited 1×
“Although, traditional Chinese herbal medicine in being applied for COVID-19 pneumonia, its effectiveness remains uncertainly [15].”
BackgroundQu, D., Zheng, B., Yao, X. S., Guan, Y., Yuan, Z.-H., Zhong, N., Lu, L., Xie, J.-P., & Wen, Y. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.031 · Cited by 75
Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro.
Zhang, C. H., Wang, Y., Liu, X. J., et al. (2005) · PubMed · Cited by 63
Mohammadpour, S., Esfahani, A. T., Halaji, M., Lak, M., & Ranjbar, R. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29868 · Cited by 58 · cited 9×
“In addition, many randomized clinical trials are being performed about Arbidol efficiency on COVID-19 infection in China [19].”
BackgroundInfluentialSelf-citationLee, S., Chung, N., Kwan, J., Kim, D. I., Kim, W. H., Kim, C. J., Kim, H. S., Park, S. H., Seo, H. S., & Shin, D. G. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.002 · Cited by 57
Drug Studies on Rett Syndrome: From Bench to Bedside
Mohan, G., Padmapriya, S., & Vellingiri, B. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04381-y · Cited by 57 · cited 3×
“Since a lot of Indian medicinal plants showed antiviral, anti-oxidant and anti-cancer activities that it may be important to consider their precise activities [72].”
BackgroundInfluentialOyero, O. G., Toyama, M., Mitsuhiro, N., Onifade, A. A., Hidaka, A., Okamoto, M., & Baba, M. (2016) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v13i6.20 · Cited by 51
Oseltamivir Treatment of Influenza in Children
Uyeki, T. M. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1150 · Cited by 49
Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis
Li, C., Bo, L., Liu, Q., & Jin, F. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.12.032 · Cited by 48 · cited 1×
“So, the administration of Ta1 can be used as drug candidate for COVID-19 treatment [37,38].”
MethodJiang, W., Shen, Q., Chen, M., Wang, Y., Zhou, Q., Zhu, X., & Zhu, X. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.002 · Cited by 38
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
Sheikhshahrokh, A., Ranjbar, R., Saeidi, E., Dehkordi, F. S., Heiat, M., Ghasemi-Dehkordi, P., & Goodarzi, H. (2020) · Iranian Journal of Public Health · doi:10.18502/ijph.v49is1.3666 · Cited by 36 · cited 1×
“In some countries, there are no options for treatment and prevention such as vaccine or specific coronavirus drugs, so, convalescent plasma therapy is an alternative strategy to decrease the course of infection in hospitalized patients [42].”
BackgroundSelf-citation(2010) · The Internet Journal of Tropical Medicine · doi:10.5580/ba9 · Cited by 33 · cited 1×
“Among them, Vitex trifolia and Sphaeranthus indicus have been shown to decrease the inflammatory cytokine level using the NF-kB pathway, an important pathway in respiratory distress in SARS-CoV [74].”
MethodToxicological studies on debitterized neem oil (Azadirachta indica)
Chinnasamy, N., Harishankar, N., Kumar, P., & Rukmini, C. (1993) · Food and Chemical Toxicology · doi:10.1016/0278-6915(93)90079-e · Cited by 27 · cited 1×
“In addition, there are some claims about banana, garlic, Juice of bittergourd, turmeric and Azadirachta indica to prevent COVID-19 but there is no supporting data [49].”
BackgroundVityala, Y. (2020) · International Journal of Research in Pharmaceutical Sciences · doi:10.26452/ijrps.v11ispl1.1973 · Cited by 26 · cited 1×
“However, the side effects of drugs, including diarrhea, nausea, vomiting and interaction with other therapeutic drugs should be considered [33].”
BackgroundAldridge, M. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/qdsef · Cited by 2
Metadata
- Authors
- Mirzaie, A., Halaji, M., Dehkordi, F. S., Ranjbar, R., & Noorbazargan, H.
- Venue
- Complementary Therapies in Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 40
- Pages
- 101214
- ISSN
- 1744-3881 (ISSN-L)
- OpenAlex
- W3036718538
- Cited by
- 164
- References
- 73
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.